肺癌放化疗后并发治疗相关性急性髓系细胞白血病1例报告并文献复习  

A report and literature review on acute myelocytic leukemia caused by chemoradiotherapy in lung cancer

作　　者：李芳 蔄雯瑜 Li Fang;Man Wenyu(Clinical Lab,Weihai Central Hospital,Weihai 264400,China)

机构地区：[1]威海市中心医院检验科,264400

出　　处：《国际医药卫生导报》2019年第22期3783-3785,共3页International Medicine and Health Guidance News

摘　　要：目的探讨肺癌治疗与继发性白血病的关系及预防策略。方法报道1例肺癌化疗后继发急性白血病患者临床资料,并进行文献复习。结果本例患者为急性髓系白血病(AML),有肺癌化疗史,化疗方案含长春瑞滨和顺铂,潜伏期为6年。该患者目前尚在治疗中,对AML治疗效果差。结论肺癌患者采用长春瑞滨和顺铂类药物化疗以及放疗可导致发生白血病的风险提高,大剂量化疗时风险进一步增高。继发性AML临床特点与原发性AML相似,预后差。Objective To explore the relationship between treatment of lung cancer and secondary leukemia and the prevention strategy.Method A case of secondary acute leukemia after chemotherapy for lung cancer was reported and reviewed.Results The case was acute myeloid leukemia(AML),with a history of chemotherapy for lung cancer.The chemotherapy program contained navelbine and cisplatin,and the incubation period was 6 years.The patient is still in treatment and has poor therapeutic effect on AML.Conclusion The risk of leukaemia can be increased in patients with lung cancer by the chemotherapy of navelbine and cisplatin and radiotherapy.The clinical characteristics of secondary AML were similar to that of primary AML,and the prognosis was poor.

关 键 词：肺癌 急性髓系白血病 继发性 抗肿瘤联合化疗方案 

分 类 号：R73[医药卫生—肿瘤]